Clinical trial
Long Term Extension Study in Patients With Primary Hyperoxaluria
NCT04042402 · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, Industry · Active, not recruiting
Key facts
| NCT number | NCT04042402 |
|---|---|
| Title | Long Term Extension Study in Patients With Primary Hyperoxaluria |
| Official title | An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria |
| Acronym | PHYOX3 |
| Lead sponsor | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease, Primary Hyperoxaluria Type 3 (PH3) |
| Intervention type | Drug |
| Interventions | DCR-PHXC |
| Enrollment | 75 |
| Start date | Jul 9, 2019 |
| Primary completion | Apr 1, 2030 |
| Completion | Apr 1, 2030 |
| First posted | Aug 2, 2019 |
| Last update posted | May 30, 2025 |
| Countries | Australia, Canada, France, Germany, Italy, Japan, Lebanon, Netherlands, Norway, Spain, Turkey (Türkiye), United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: